1 terminated, 1 withdrawn. 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 2 | Terminated 1, Withdrawn 1 |
Follow Relapse: new trials by email Literature Review of Relapse trials Research Report on Relapse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Relapse Prevention in Stimulant Use Disorder Contrave 8Mg-90Mg Extended-Release Tablet, Bupropion - Stimulant Use, Relapse | Early Phase 1 | Withdrawn | University of California, Los Angeles | 2023-06-11 | 2023-09-22 | |
| Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers Betaine, Peginterferon alpha 2a, Ribavirin - Chronic Hepatitis C, Genotype 1 | Early Phase 1 | Terminated | University of Nebraska | 2 | 2009-05-01 | 2023-11-30 |
Recurrence (2) · Attention Deficit Disorder with Hyperactivity (1) · Hepatitis C, Chronic (1)
Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Attention Deficit and Disruptive Behavior Disorders (1) · Blood-Borne Infections (1) · Chronic Disease (1) · Communicable Diseases (1) · Digestive System Diseases (1) · Flaviviridae Infections (1) · Hepatitis (1) · Hepatitis C (1) · Hepatitis, Chronic (1) · Hepatitis, Viral, Human (1) · Infections (1) · Liver Diseases (1)
Betaine (1) · Bupropion (1) · Ribavirin (1) · bupropion hydrochloride, naltrexone hydrochoride drug combination (1) · peginterferon alfa-2a (1)
University of California, Los Angeles (1) · University of Nebraska (1)
United States (2)
Edythe D London, Ph.D. (1) · Mark E Mailliard, MD (1)